Cannabinoid firm GW Pharmaceuticals says it is “inspection ready” as it prepares for potential US approval of its epilepsy candidate Epidiolex (cannabidiol or CBD). Epidiolex, and oral solution of pure plant-derived cannabidiol, or CBD, is GW’s lead candidate in development for severe, orphan, … Read More
The post GW prepping for mid-2018 CBD epilepsy candidate approval in US appeared first on Dagga Magazine.